I
n their letter to the editor, Damon et al.
(1) presented their observation of a local allergic reaction to insulin detemir. According to the patient's clinical appearance, they classified it as a type III allergy. Another case of a severe injection site reaction to insulin detemir was recently reported by Blumer (2). The described reactions to insulin injection are characteristically similar to a case of type III allergy we managed in our outpatient department in July 2004. We decided to start with insulin detemir to improve glycemic control in the 56-year-old female patient with type 1 diabetes. Diabetes was known for 40 years, and the last 2 years she was treated with intermediate-acting NPH insulin (Insulatard Human; Novo Nordisk) twice daily in combination with insulin aspart (NovoRapid; Novo Nordisk) before each meal. For a short period, the patient received insulin glargine (Lantus; Sanofi-Aventis) in place of NPH insulin. Neither under this therapy nor any other former medication did the patient describe an allergic reaction. Starting with the first injection of detemir, the patient developed local alterations quite similar to that which Darmon et al. reported. We also observed the development of dense, nonerythematous, and painful nodules with a diameter of 0.5 cm that occurred 4 -6 h after insulin injection. These reactions persisted on average for 4 -5 days and disappeared without intervention. The close temporal and local connection with injection of insulin detemir emphasizes its causal role in this case of allergy. Dermatological testing confirmed the type III reaction, while there was no indication of a type IV allergy. In conclusion, allergy to insulin detemir is rare and previously unreported in the literature, but the observation by Darmon et al. seems to be not the only one. 
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D
iabetic macular edema is often associated with multiple comorbid systemic conditions (1). In a pilot study (2), multifactorial interventions in clinically significant macular edema (CSME) led to a decrease in retinal thickness. However, the effect of these interventions, before laser photocoagulation, on the outcome of diabetic macular edema has not been studied.
In a prospective study, 125 patients (180 eyes; 72 men and 53 women; median age 55 years [range 38 -72]) completed a minimum follow-up of 1 year (median 1.8 years [range 1.0 -2.7]). All underwent multifactorial interventions, including initiation of insulin therapy (n ϭ 47), newer oral hypoglycemic agents (n ϭ 70), angiotensin receptor blockers (n ϭ 59), ACE inhibitors (n ϭ 100), lipidlowering drugs (n ϭ 107), iron supplements (n ϭ 22), and antihypertensive agents (n ϭ 100), in an attempt to optimize control. Patients were encouraged to meet the targets and maintain them throughout (3). Focal laser photocoagulation was done after 4 -6 weeks of initiating control.
Final visual outcomes were compared in the "complete control" (all target values achieved) and the "partial control" (target values not achieved for one or more factors) groups. At baseline, demographic and lipid profiles of two groups were comparable, whereas blood pressure, HbA 1c , hemoglobin, and proteinuria were significantly worse in the partial control group. CSME was bilateral in 55 subjects (110 eyes) and unilateral in 70 (70 eyes). Median interval from diagnosis of diabetes was 10 years (mean 7.2 Ϯ 2.97 years [range 0.5-25.0]) There was statistically significant improvement in bestcorrected visual acuity (BCVA) in the complete control group (P Ͻ 0.001). The improvement of BCVA by three or more lines was achieved in 25 (29.1%) eyes in the complete control group compared with 20 (21.3%) eyes in the partial control group. The BCVA deteriorated by three or more lines in 14 (14.9%) eyes in the partial control group compared with none in the complete control group.
The ETDRS (Early Treatment Diabetic Retinopathy Study) (4) reported improvement in visual acuity up to one line in 16%, vision remaining unchanged in 77%, and worsening by three lines in 7% of the treated eyes. Improvement of visual acuity by 15 letters (three lines or one-half the initial visual angle) was uncommon (Ͻ3%) (5). The ETDRS, however, did not address the issue of systemic control in patients who were candidates for receiving focal laser photocoagulation. In the present series, the complete control group showed three or more lines improvement (one-half the initial visual angle) in 29.1% and stabilization of visual acuity in 70.9%. Even in the partial control group where multifactorial control was attempted, three or more lines of visual acuity improvement was seen in 21.3% of the treated eyes, while the vision remained unchanged in 63.8%. Our study, though limited, has shown better visual outcome than is obtainable by the current standard of care strategies of laser photocoagulation, without enforcing systemic control. In view of our observations, the strategy of multifactorial interventions in CSME before laser photocoagulation needs to be addressed in a larger number of patients. • 
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Continuous Glucose Monitoring System With an Alarm
A tool to reduce hypoglycemic episodes in pregnancy with diabetes B ased on strong evidence that hyperglycemia is harmful to the fetus, guidelines recommend strict diabetes regulation during pregnancy, but the rate of severe hypoglycemia is four times the rate before pregnancy (1). A newly developed tool of continuous glucose monitoring with display and alarm might be helpful in reducing the risk of recurrent episodes of severe hypoglycemia during pregnancy.
A 32-year-old woman with a history of diabetes for 21 years experienced 18 episodes of severe hypoglycemia the year preceding pregnancy, despite treatment with an insulin pump, frequent home blood glucose measurements, and HbA 1c (A1C) ϳ7.5%. Episodes of severe hypoglycemia were prospectively recorded from gestational week 7. Three 24-h home blood glucose measurements (eight-point profiles), A1C, and insulin dose were registered prospectively at gestational week 7, 14, 22, 27, and 33.
Between 7 and 16 weeks of gestation, the patient experienced seven episodes of severe hypoglycemia without any obvious explanations of the events. Treatment was intramuscular glucagon in four cases and juice in the remaining three. Mean blood glucose was 1.5 mmol/l (range 1.0 -1.9). Based on this experience, continuous glucose monitoring with a display and programmed to alarm at glucose values Ͻ4.0 mmol/l was introduced at gestational week 17 (Guardian; Medtronic Minimed, Northridge, CA) (2).
During pregnancy, mean blood glucose remained stable between 6 and 8 mmol/l and A1C declined from 6.7 to 6.2%. Insulin dose was 45 IE before pregnancy and 43 IE at week 33. After the Guardian was introduced, the patient only experienced one episode of severe hypoglycemia at gestational week 19 at night while the Guardian was out of function.
The observed glucose values below 2.2 mmol/l were eliminated. Spontaneous rupture of membranes occurred at gestational week 36, and a healthy baby of 2,982 g was born. The woman continued carrying the device with no hypoglycemic events for 3 months after delivery.
Introduction of a Guardian at gestational week 17 led to a dramatic decrease in the occurrence of episodes of severe hypoglycemia from 1.5 episodes/month to 0.3 episodes/month in the remaining part of pregnancy in combination with a decline in A1C to 6.2%. The device was well tolerated by the patient. Limitations of the Guardian are the Ͻ100% safety and accuracy of the device (2). In addition, three daily calibrations are required.
A Guardian might be a helpful tool in pregnant patients with type 1 diabetes who are susceptible to frequent episodes of severe hypoglycemia. Also, nonpregnant patients with type 1 diabetes and hypoglycemia unawareness might benefit from a Guardian. Frequent severe hypoglycemic events are expensive from a socioeconomic point of view, and the costeffectiveness using a Guardian would be of interest to evaluate in the future. 
